Last checked at 27 Nov 2023 16:12
London close: Stocks start week in subdued state
(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat5
AZN Share
Trades11,360
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings1
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
9,915.00
Bid:
9,914.00
Ask:
9,916.00
Change:
-61.00 (-0.61%)
Spread:
2.00 (0.02%)
Open:
9,956.00
High:
9,984.00
Low:
9,851.00
Prev. Close:
9,976.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.27 Nov 2023 09:20
LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more23 Nov 2023 18:41
IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000
AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.
Read more20 Nov 2023 10:49
AstraZeneca launches new life sciences tech innovation firm Evinova
(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.
Read more17 Nov 2023 15:20
London close: Stocks higher despite weaker retail sales data
(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.
Read more17 Nov 2023 12:00
LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales
(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.
Read more17 Nov 2023 09:03
LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss
(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.
Read more17 Nov 2023 08:31
TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer
(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.
Read more17 Nov 2023 07:58
LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval
(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.
Read more17 Nov 2023 07:16
AstraZeneca gets US approval for breast cancer treatment
(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.
Read more14 Nov 2023 10:51
TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial
(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.
Read more14 Nov 2023 09:22
AstraZeneca's latest lung cancer trial fails its primary endpoint
(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.
Read more13 Nov 2023 09:45
LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read more9 Nov 2023 15:02
London close: Stocks gain as investors await Powell speech
(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.
Read more9 Nov 2023 12:06
LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear
(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.
Read more